Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Adicet Bio Inc (Adicet Bio) is a clinical-stage biotechnology company that focuses on the discovery and development of allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company’s pipeline products include ADI-001 which targets lupus nephritis, systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myopathy, stiff person syndrome and anti-neutrophil cytoplasmic autoantibody -associated vasculitis and rheumatoid arthritis; and ADI-212 for metastatic castration-resistant prostate cancer. It utilizes proprietary cell platform for activation, engineering and expansion of gamma delta T cells which allows for generation of cell therapy products. The company operates in the US and Israel. Adicet Bio is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
3rd Floor, 131 Dartmouth Street, Boston, Massachusetts, 02116
Website
www.adicetbio.com
Telephone
1 650 5039095
No of Employees
102
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ACET (NASD)
EPS
XYZ
Net Income (2024)
XYZ
0.3%
(2024 vs 2023)
Market Cap*
$77.3M
Net Profit Margin (2021)
XYZ
0.0%
(2024 vs 2023)
* As of and is in US$
Products and Services
| Products |
|---|
| Pipleline |
| ADI-001: |
| Lupus Nephritis |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Adicet Bio Inc | Adaptimmune LLC | Allogene Therapeutics Inc | Arsenal Biosciences Inc | Cogent Biosciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Boston | Philadelphia | South San Francisco | San Francisco | Waltham |
| State/Province | Massachusetts | Pennsylvania | California | California | Massachusetts |
| No. of Employees | 102 | - | 150 | - | 258 |
| Entity Type | Public | Private | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Chen Schor | Chief Executive Officer; Director; President | Executive Board | 2020 | 52 |
| Nick Harvey | Chief Financial Officer | Senior Management | 2020 | 64 |
| Donald Healey, Ph.D. | Chief Technology Officer | Senior Management | 2020 | 63 |
| Julia Maltzman, M.D. | Chief Medical Officer | Senior Management | 2025 | 57 |
| Blake Aftab, Ph.D. | Chief Scientific Officer | Senior Management | 2021 | 43 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer